Plain-English translation of NCT06881537 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a combination of four medications — including chemotherapy (CapeOX), , and — given before surgery to shrink colorectal cancer that has come back in the same area after initial treatment. The goal is to see if this combination can help doctors remove all the cancer during a second surgery and improve your chances of staying cancer-free.
Colorectal cancer that returns in the same location after surgery is difficult to treat, and doctors want to find better ways to shrink it before operating again so they can remove it more completely and patients can have better long-term outcomes.
You likely qualify if…
You likely don't qualify if…
You would receive four medications intravenously or by mouth over a 12-week period, given in cycles every 3 weeks. The treatment includes two chemotherapy drugs (one taken by mouth twice daily for 2 weeks, one given by IV), plus two IV infusions on the first day of each cycle. After completing 4 cycles of treatment, you would undergo surgery to remove the remaining cancer. Throughout the trial, you'll have regular blood tests and imaging scans to monitor how well the treatment is working and how you're tolerating it.
AI-generated summary from trial data · Jul 3, 2026 · Not medical advice
China
Phase
Testing effectiveness
Sponsor
Shanghai Changzheng Hospital
Enrollment target
~15 participants
Started
June 2024
Primary completion
June 2025
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years – 75 Years
Last updated on clinicaltrials.gov in March 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Haiyang Zhou, MD
Shanghai Changzheng Hospital
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.